Breakthrough Therapy Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
0NDV | A | Morphosys AG O.N. | 0.03 | |
0MGB | D | Genmab | 0.00 | |
0H22 | F | Bioinvent International AB | 0.00 |
Related Industries:
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
MMS | C | Lyxor Index Fund | 0.53 | |
CES1 | A | iShares MSCI EMU Small Cap UCITS ETF | 0.53 | |
UB69 | A | UBS MSCI EMU Small Cap UCITS ETF | 0.52 | |
XXSC | A | db x-trackers MSCI Europe Small Cap Index UCITS ETF | 0.23 | |
VGER | B | Vanguard Germany All Cap UCITS ETF EUR Distributing GBP | 0.16 |
Compare ETFs
- Breakthrough Therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "breakthrough therapy" designation is not intended to imply that a drug is actually a "breakthrough" or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Popular Now
Recent Comments
- TraderMike on Trades of the Week: Jan 8 - Jan 12, 2024
- Magneto296 on Trades of the Week: Jan 8 - Jan 12, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
- SwingTradeBot on Market Recap for Friday, February 23, 2024
From the Blog
Featured Articles